focus -WSS

focus

author：leisure time 2025-08-18 06:01:38 Page View：92

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health
Next article： Jerome Adams on the need for new antivirals for Covid

explore

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Glen Campbell's doctor discusses his public struggle with Alzheimer's

GlenCampbellperformsinIndio,Calif.,in2008.MichaelBuckner/GettyImagesGlenCampbell’sdecades-longmusica

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

1:00PresidentialcandidateFernandoVillavicenciospeaksduringacampaigneventataschoolminutesbeforehewass

focus

knowledge

explore

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested